Factors predicting the outcome of disease activity assessment in Crohn's disease

Inflammatory Bowel Diseases

Volumn 15, Issue 12, 2009, Pages 1859-1866

  Stjernman, Henrik ^a   Tysk, Curt ^b,c   Almer, Sven ^d   Ström, Magnus ^d   Hjortswang, Henrik ^d  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^c ÖREBRO UNIVERSITY   (Sweden)

^d LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Crohn's disease; Disease activity; Inflammatory bowel disease; Outcome assessment

Indexed keywords

C REACTIVE PROTEIN;

ADULT; ANUS FISTULA; ARTICLE; COMORBIDITY; CROHN DISEASE; DISEASE ACTIVITY; FEMALE; HUMAN; INTESTINE FISTULA; INTESTINE RESECTION; INTESTINE STENOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; RISK ASSESSMENT; SCORING SYSTEM; SEX DIFFERENCE; SMOKING;

ADULT; C-REACTIVE PROTEIN; CLINICAL TRIALS AS TOPIC; COLECTOMY; CONSTRICTION, PATHOLOGIC; CROHN DISEASE; FEMALE; HUMANS; MALE; PROGNOSIS; REGRESSION ANALYSIS; SEVERITY OF ILLNESS INDEX; SMOKING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 72549089384     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20975     Document Type: Article

References (32)

1. Stange EF, Travis SP, Vermeire S, et al. European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut. 2006;55(suppl 1):i1-15.
2. Best WR, Becktel JM, Kern F, et al. Development of a Crohn's disease activity index. Gastroenterology. 1976;70:439-444.
3. Best WR, Becktel JM, Singleton JW. Re-derived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology. 1979;77:843-846.
4. Mee AS, Brown DJ, Jewell DP. Crohn's disease activity index - is it useful? Gut. 1978;19:A990.
5. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet. 1980;1:514.
6. Best WR, Becktel JM. The Crohn's disease activity index as a clinical instrument. In: Booth CC, Waterman I, Pena S, Haex CC, eds. 2nd International Workshop on Crohn's disease. Nordwijk/zee, Holland: de Baak; 1980.
7. Wright JP, Marks IN, Parfitt A. A simple clinical index of Crohn's disease activity - the Cape Town index. S Afr Med J. 1985;68:502-503. (Pubitemid 16198618)
8. De Dombal FT, Softley A. IOIBD report no 1: Observer variation in calculating indices of severity and activity in Crohn's disease. Gut. 1987;28:474-481. (Pubitemid 17056886)
9. van Hees PA, van Elteren PH, van Tongeren JH, et al. An index of inflammatory activity in patients with Crohn's disease. Gut. 1980;21:279-286. (Pubitemid 10056059)
10. Gomes P, Du Boulay C, Holstock G, et al. Relationship between disease activity indices and colonoscopic findings in patients with colonic inflammatory bowel disease. Gut. 1986;27:92-95. (Pubitemid 16134482)
11. Crama-Bohbouth G, Pena AS, Biemond I, et al. Are activity indices helpful in assessing active intestinal inflammation in Crohn's disease? Gut. 1989;30:1236-1240.
12. Acciuffi S, Ghosh S, Ferguson A. Strengths and limitations of the Crohn's disease activity index, revealed by an objective gut lavage test of gastrointestinal protein loss. Aliment Pharmacol Ther. 1996;10:321-326. (Pubitemid 26173879)
13. Sostegni R, Daperno M, Pera A, et al. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther. 2003;17(suppl 2):11-17. (Pubitemid 36831453)
14. Irvine EJ. Usual therapy improves perianal Crohn's disease as measured by a new disease activity index. McMaster IBD Study Group. J Clin Gastroenterol. 1995;20:27-32.
15. Sandborn WJ, Feagan BG, Sutherland LR, et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology. 2002;122:512-530.
16. Hanauer SB, Feagan BG, Rutgeerts P, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359:1541-1549. (Pubitemid 34621118)
17. Sandborn WJ, Hanauer SB, Pollack PF, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007;56:1232-1239. (Pubitemid 47300424)
18. Sandborn WJ, Colombel JF, Rutgeerts P, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med. 2005;353:1912-1925. (Pubitemid 41565956)
19. Gourtsoyiannis N, Papanikolaou N, Roussomoustakaki M, et al. Assessment of Crohn's disease activity in the small bowel with MR and conventional enteroclysis: preliminary results. Eur Radiol. 2004;14:1017-1024. (Pubitemid 38787247)
20. Rapaccini GL, Pompili M, Gasbarrini G, et al. Contrast-enhanced power Doppler of the intestinal wall in the evaluation of patients with Crohn's disease. Scand J Gastroenterol. 2004;39:188-194. (Pubitemid 38253633)
21. Stjernman H, Grännö C, Bodemar G, et al. Evaluation of the Inflammatory Bowel Disease Questionnaire in Swedish patients with Crohn's disease. Scand J Gastroenterol. 2006;41:934-943. (Pubitemid 43995469)
22. Stjernman H, Grännö C, Hjortswang H, et al. Short Health Scale: a valid, reliable, and responsive instrument for subjective health assessment in Crohn's disease. Inflamm Bowel Dis. 2007;14:47-52 (Pubitemid 351196868)
23. Winship DH, Summers RW, Kern F Jr, et al. National cooperative Crohn's disease study: design and conduct of the study. Gastroenterology. 1979;77:829-842. (Pubitemid 9257851)
24. Sandler RE, Jordan CJ, Kupper LL. Development of a Crohn's index for survey research. J Clin Epidemiol. 1988;41:451-458.
25. Castiglione F, Del Vecchio Blanco G, Mazzacca G, et al. Orocecal transit time and bacterial overgrowth in patients with Crohn's disease. J Clin Gastroenterol. 2000;31:63-66. (Pubitemid 30430250)
26. Nyhlin H, Merrick MV, Eastwood MA. Bile acid malabsorption in Crohn's disease and indications for its assessment using SeHCAT. Gut. 1994;35:90-93. (Pubitemid 24059479)
27. Bernklev T, Jahnsen J, Moum B, et al. Health-related quality of life in patients with inflammatory bowel disease measured with the short form-36: psychometric assessments and a comparison with general population norms. Inflamm Bowel Dis. 2005;11:909-918. (Pubitemid 41428850)
28. Hjortswang H, Järnerot G, Curman B, et al. The influence of demographic and disease-related factors on health-related quality of life in inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2003;15:1011-1012. (Pubitemid 37094302)
29. Saibeni S, Cortinovis I, de Franchis R, et al. Gender and disease activity influence health-related quality of life in inflammatory bowel diseases. Hepatogastroenterology. 2005;52:509-515. (Pubitemid 40469458)
30. Chang L, Toner BB, Sperber AD, et al. Gender, age, society, culture, and the patient's perspective in the functional gastrointestinal disorders. Gastroenterology. 2006;130:1435-1446.
31. Simrén M, Axelsson J, Björnsson ES, et al. Quality of life in inflammatory bowel disease in remission: the impact of IBS-like symptoms and associated psychological factors. Am J Gastroenterol. 2002;97:389-396.
32. Vermeire S, van Assche G, Rutgeerts P. Review article: altering the natural course of Crohn's disease-evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. (Pubitemid 44902859)